Aegerion Pharmaceuticals (AEGR) 25.15 $AEGR
Aegerion Pharmaceuticals to Announce Fourth-Quarter and Full-Year 2014 Financial Results on Thursday, February 26
GlobeNewswire - Thu Feb 12, 6:55AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EST on Thursday, February 26, 2015, to provide a business update and to discuss its fourth-quarter and full-year 2014 financial and operating results.
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals awards inducement stock options to 14 new employees under inducement programme
M2 - Wed Feb 11, 4:42AM CST
Biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) disclosed on Tuesday the grant of inducement stock options to purchase an aggregate of 39,200 shares of common stock to 14 new employees under the inducement stock option programme.
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Tue Feb 10, 3:45PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on February 2, 2015, Aegerion granted stock options to purchase an aggregate of 39,200 shares of common stock to 14 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $23.36, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
AEGR: 25.15 (+0.88)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
Aegerion Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:10PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 2015 Leerink Global Healthcare Conference being held in New York City. Marc Beer, chief executive officer of Aegerion, is scheduled to present on Thursday, February 12, 2015 at 2:15 p.m. EST.
AEGR: 25.15 (+0.88)
Commit To Purchase Aegerion Pharmaceuticals At $15, Earn 12% Annualized Using Options
at The Street - Wed Feb 04, 10:36AM CST
Investors eyeing a purchase of Aegerion Pharmaceuticals Inc stock, but cautious about paying the going market price of $23.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AEGR: 25.15 (+0.88)
Aegerion (AEGR) Investigated by Former Louisiana Attorney General and Special Prosecutor Richard P. Ieyoub and the Firm of Ieyoub O'Bell & Myers, LLC
Business Wire - Wed Jan 28, 9:14AM CST
Former Attorney General of Louisiana Richard P. Ieyoub and the firm of Ieyoub O'Bell & Myers, LLC ("IOM"
(www.iomcounsel.com) are investigating events at Aegerion Pharmaceuticals, Inc. (AEGR) for possible breaches of fiduciary duties by the management and Board of Directors.
AEGR: 25.15 (+0.88)
Capstone Could Succeed with AEM-28 Where Aegerion and Sanofi Failed
ACCESSWIRE - Wed Jan 28, 8:01AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2015 / Cholesterol-reducing statins like Pfizer's (NYSE
FE) Lipitor may be the best selling prescription drug class in history, but for one kind of cholesterol disease, statins are just a pharmacological drop in the bucket.
ISIS: 63.86 (-0.43), PFE: 34.64 (-0.23), AEGR: 25.15 (+0.88), SNY: 49.42 (+0.82)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RXDX: 6.91 (+0.06), NVAX: 8.80 (+0.40), ADHD: 6.92 (+0.73), AEGR: 25.15 (+0.88), NVC.TO: 11.27 (-0.23), NVCN: 9.08 (-0.17)
Critical Alerts For Ford, BlackBerry, Aegerion Pharmaceuticals, Yahoo! and NewLink Genetics Released By InvestorsObserver
PR Newswire - Thu Jan 15, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for F, BBRY, AEGR, YHOO and NLNK.
YHOO: 44.42 (+0.50), F: 16.30 (-0.06), BBRY: 10.09 (+0.23), NLNK: 38.84 (+1.51), AEGR: 25.15 (+0.88)
Aegerion Reveals Preliminary 2014 Results and 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:00PM CST
Aegerion Pharmaceuticals, Inc. (AEGR) announced preliminary 2014 net product sales estimates and an outlook for 2015 besides providing pipeline updates.
AMGN: 153.48 (+0.30), AEGR: 25.15 (+0.88), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Aegerion reports preliminary results and 2015 outlook as well as an SEC inquiry into sales practices
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 9:13AM CST
AEGR: 25.15 (+0.88)
Aegerion Target of SEC Probe Related to Drug Sales Practices
at The Street - Tue Jan 13, 8:12AM CST
Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals Reports Preliminary 2014 Net Product Sales, Its Outlook for 2015 and Other Business Updates
GlobeNewswire - Mon Jan 12, 6:07AM CST
- Company Completes Acquisition of MYALEPT(R)
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals Completes Acquisition of MYALEPT(R)
GlobeNewswire - Mon Jan 12, 6:00AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has completed the acquisition of MYALEPT(R) (metreleptin) for injection, an orphan drug product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy (GLD). Execution of the asset purchase agreement setting forth the terms of the acquisition was announced on November 6, 2014. Aegerion paid $325 million upfront to acquire the global rights to develop, manufacture and commercialize MYALEPT, subject to an existing distributor license with Shionogi covering Japan, South Korea and Taiwan.
AEGR: 25.15 (+0.88)
A Tale of Two Rare Disease Stocks: NPS Pharma Bought for $5.2B, Aegerion Struggles Alone.
at The Street - Sun Jan 11, 11:15PM CST
A successful rare-disease drug launch and the development of a second product made NPS an attractive takeout target.
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03), AEGR: 25.15 (+0.88)
Direction of Market Influences - Research Report on CyrusOne, DISH Network, Dave & Buster's Entertainment, Del Frisco's Restaurant Group, and Aegerion
PR Newswire - Wed Jan 07, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including CyrusOne (NASDAQ: CONE), DISH Network (NASDAQ: DISH), Dave & Buster's Entertainment (NASDAQ: PLAY), Del Frisco's Restaurant Group (NASDAQ: DFRG), and Aegerion (NASDAQ: AEGR). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
DFRG: 19.14 (-0.03), CONE: 28.78 (-0.25), AEGR: 25.15 (+0.88), PLAY: 29.51 (-0.12), DISH: 77.20 (-0.16)
Aegerion Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 3:39PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 33 Annual J.P. Morgan Healthcare Conference being held in San Francisco. Marc Beer, chief executive officer of Aegerion, is scheduled to present on Monday, January 12, 2015 at 4:30 p.m. PST (7:30 p.m. EST).
JPM: 59.67 (+0.10), AEGR: 25.15 (+0.88)
Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 90.70 (+0.93), NWBO: 6.07 (+0.13), GILD: 101.90 (+1.10), DNDN: 0.13 (-0.02), ICPT: 209.12 (+7.12), JUNO: 40.52 (+0.18), GALE: 1.68 (+0.06), AGIO: 118.55 (+0.11), AEGR: 25.15 (+0.88), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16)
Aegerion Pharmaceuticals to Announce Fourth-Quarter and Full-Year 2014 Financial Results on Thursday, February 26
GlobeNewswire - Thu Feb 12, 6:55AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EST on Thursday, February 26, 2015, to provide a business update and to discuss its fourth-quarter and full-year 2014 financial and operating results.
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals awards inducement stock options to 14 new employees under inducement programme
M2 - Wed Feb 11, 4:42AM CST
Biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) disclosed on Tuesday the grant of inducement stock options to purchase an aggregate of 39,200 shares of common stock to 14 new employees under the inducement stock option programme.
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Tue Feb 10, 3:45PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on February 2, 2015, Aegerion granted stock options to purchase an aggregate of 39,200 shares of common stock to 14 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $23.36, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
AEGR: 25.15 (+0.88)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
Aegerion Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:10PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 2015 Leerink Global Healthcare Conference being held in New York City. Marc Beer, chief executive officer of Aegerion, is scheduled to present on Thursday, February 12, 2015 at 2:15 p.m. EST.
AEGR: 25.15 (+0.88)
Commit To Purchase Aegerion Pharmaceuticals At $15, Earn 12% Annualized Using Options
at The Street - Wed Feb 04, 10:36AM CST
Investors eyeing a purchase of Aegerion Pharmaceuticals Inc stock, but cautious about paying the going market price of $23.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AEGR: 25.15 (+0.88)
Aegerion (AEGR) Investigated by Former Louisiana Attorney General and Special Prosecutor Richard P. Ieyoub and the Firm of Ieyoub O'Bell & Myers, LLC
Business Wire - Wed Jan 28, 9:14AM CST
Former Attorney General of Louisiana Richard P. Ieyoub and the firm of Ieyoub O'Bell & Myers, LLC ("IOM"
(www.iomcounsel.com) are investigating events at Aegerion Pharmaceuticals, Inc. (AEGR) for possible breaches of fiduciary duties by the management and Board of Directors. AEGR: 25.15 (+0.88)
Capstone Could Succeed with AEM-28 Where Aegerion and Sanofi Failed
ACCESSWIRE - Wed Jan 28, 8:01AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2015 / Cholesterol-reducing statins like Pfizer's (NYSE
FE) Lipitor may be the best selling prescription drug class in history, but for one kind of cholesterol disease, statins are just a pharmacological drop in the bucket. ISIS: 63.86 (-0.43), PFE: 34.64 (-0.23), AEGR: 25.15 (+0.88), SNY: 49.42 (+0.82)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RXDX: 6.91 (+0.06), NVAX: 8.80 (+0.40), ADHD: 6.92 (+0.73), AEGR: 25.15 (+0.88), NVC.TO: 11.27 (-0.23), NVCN: 9.08 (-0.17)
Critical Alerts For Ford, BlackBerry, Aegerion Pharmaceuticals, Yahoo! and NewLink Genetics Released By InvestorsObserver
PR Newswire - Thu Jan 15, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for F, BBRY, AEGR, YHOO and NLNK.
YHOO: 44.42 (+0.50), F: 16.30 (-0.06), BBRY: 10.09 (+0.23), NLNK: 38.84 (+1.51), AEGR: 25.15 (+0.88)
Aegerion Reveals Preliminary 2014 Results and 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:00PM CST
Aegerion Pharmaceuticals, Inc. (AEGR) announced preliminary 2014 net product sales estimates and an outlook for 2015 besides providing pipeline updates.
AMGN: 153.48 (+0.30), AEGR: 25.15 (+0.88), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Aegerion reports preliminary results and 2015 outlook as well as an SEC inquiry into sales practices
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 9:13AM CST
AEGR: 25.15 (+0.88)
Aegerion Target of SEC Probe Related to Drug Sales Practices
at The Street - Tue Jan 13, 8:12AM CST
Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals Reports Preliminary 2014 Net Product Sales, Its Outlook for 2015 and Other Business Updates
GlobeNewswire - Mon Jan 12, 6:07AM CST
- Company Completes Acquisition of MYALEPT(R)
AEGR: 25.15 (+0.88)
Aegerion Pharmaceuticals Completes Acquisition of MYALEPT(R)
GlobeNewswire - Mon Jan 12, 6:00AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has completed the acquisition of MYALEPT(R) (metreleptin) for injection, an orphan drug product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy (GLD). Execution of the asset purchase agreement setting forth the terms of the acquisition was announced on November 6, 2014. Aegerion paid $325 million upfront to acquire the global rights to develop, manufacture and commercialize MYALEPT, subject to an existing distributor license with Shionogi covering Japan, South Korea and Taiwan.
AEGR: 25.15 (+0.88)
A Tale of Two Rare Disease Stocks: NPS Pharma Bought for $5.2B, Aegerion Struggles Alone.
at The Street - Sun Jan 11, 11:15PM CST
A successful rare-disease drug launch and the development of a second product made NPS an attractive takeout target.
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03), AEGR: 25.15 (+0.88)
Direction of Market Influences - Research Report on CyrusOne, DISH Network, Dave & Buster's Entertainment, Del Frisco's Restaurant Group, and Aegerion
PR Newswire - Wed Jan 07, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including CyrusOne (NASDAQ: CONE), DISH Network (NASDAQ: DISH), Dave & Buster's Entertainment (NASDAQ: PLAY), Del Frisco's Restaurant Group (NASDAQ: DFRG), and Aegerion (NASDAQ: AEGR). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
DFRG: 19.14 (-0.03), CONE: 28.78 (-0.25), AEGR: 25.15 (+0.88), PLAY: 29.51 (-0.12), DISH: 77.20 (-0.16)
Aegerion Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 3:39PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 33 Annual J.P. Morgan Healthcare Conference being held in San Francisco. Marc Beer, chief executive officer of Aegerion, is scheduled to present on Monday, January 12, 2015 at 4:30 p.m. PST (7:30 p.m. EST).
JPM: 59.67 (+0.10), AEGR: 25.15 (+0.88)
Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 90.70 (+0.93), NWBO: 6.07 (+0.13), GILD: 101.90 (+1.10), DNDN: 0.13 (-0.02), ICPT: 209.12 (+7.12), JUNO: 40.52 (+0.18), GALE: 1.68 (+0.06), AGIO: 118.55 (+0.11), AEGR: 25.15 (+0.88), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16)
